Loading stock data…
Turn Therapeutics Inc. (TTRX)
$12.66+2.86 (+29.18%)
Market ClosedLast close Sep 8
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Turn Therapeutics Inc. in the Healthcare sector is trading at $12.66 with a market capitalization of $190M. Wall Street consensus targets $26.00 (1 analysts), implying a +105.4% move over the next 12 months. The stock is currently 52% below its 52-week high of $26.50, remaining 136.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +105.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | $0 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | -$1.37M | — | — |
| Net Income | — | — | -$1.24M | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$190.05M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.90%
Volume
Today's trading volume
320,420
Recent News
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Turn Therapeutics (NASDAQ:TTRX) outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoing trial. Brad Burn
Turn Therapeutics’ stock jumps on AD data and trial expansion
More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
Turn Therapeutics (TTRX) said Tuesday that a comprehensive interim analysis of its phase 2 trial eva
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics (NASDAQ:TTRX) executives outlined the company’s focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an Oppenheimer-hosted event. CEO and founder Bradley Burnam, joined by CFO Zuraiz Chaudhary, emphasized the company
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...